at page 109, line 4, insert —)— between "1986" and ".";

at page 109, line 24, replace the second "Ed." with —ed.—;

at page 132, line 4, insert —which— between "mice" and "predictably".

IN THE SEQUENCE LISTING:

Please replace the sequence listing in the above-captioned application with the attached substitute SEQUENCE LISTING into the above-captioned application. A disk copy of the SEQUENCE LISTING and verified statement also accompany this response.

IN THE CLAIMS:

Please cancel claims 1-24 and 41 without prejudice or disclaimer.

Please add claims 42-64 as follows:

—42. A method of claim 25, wherein the conjugate is selected from the group consisting of OPL98104, OPL98112, OPL98108, OPL98102, OPL98110, OPL98106, OPL98101, OPL98109, OPL98105, OPL98103, OPL98111 and OPL98107.—

—43. The method of claim 25, wherein the conjugate comprises a targeted agent and a chemokine receptor targeting agent, or a portion thereof, wherein the conjugate binds to a chemokine receptor resulting in internalization of the targeted agent in cells bearing the receptor.—

—44. The method of claim 43, wherein the conjugate comprises the following components: (chemokine receptor targeting agent)$_n$, (L)$_q$ and (targeted agent)$_m$, wherein:

L is a linker for linking the chemokine receptor targeting agent to a targeted agent;

chemokine receptor targeting agent is any moiety that selectively binds to a chemokine receptor;

m and n, which are selected independently, are at least 1; and

q is 0 or more as long as the resulting conjugate binds to the targeted receptor, is internalized and delivers the targeted agent;

the resulting conjugate binds to a receptor that interacts with and internalizes a chemokine, whereby the targeted agent(s) is internalized in a cell bearing the receptor; and

when the conjugate contains a plurality of targeted agents the targeted agents are the same or different, and when the conjugate contains a plurality of chemokine receptor targeting agents the targeting agents are the same or different.—

—45. The method of claim 44, wherein m and n, which are selected independently, are 1-6.—

—46. The method of claim 44, wherein q is 1, n is 2 and m is 1.

—47. The method of claim 43, wherein the chemokine receptor targeting agent is a chemokine, an antibody that specifically binds to a chemokine receptor or a fragment of the chemokine or antibody, wherein the fragment binds to the receptor and internalizes the targeted agent.—

—48. The method of claim 43, wherein the chemokine receptor targeting agent specifically binds to chemokine receptors on activated leukocytes.—

—49. The method of claim 43, wherein the chemokine receptor targeting agent specifically binds to chemokine receptors on cells selected from mononuclear phagocytes (MNP), leukocytes, natural killer cells, dendritic cells, T lymphocytes and B lymphocytes.—

—50. The method of claim 49, wherein the leukocytes are selected basophils, neutrophils, eosinophils, and combinations of any two or more thereof.—

—51. The method of claim 43, wherein the targeted agent is a toxin, a nucleic acid or a therapeutic protein.

—52. The method of claim 43, wherein the chemokine receptor targeting agent and targeted agent are linked directly via a covalent or ionic linkage.—

—53. The method of claim 43, wherein the chemokine receptor targeting agent and targeting agent are joined via a linker.—

—54. The method of claim 53, wherein the linker is a peptide linkage, a polypeptide or is chemical linker.—

—55. The method of claim 29, wherein the conjugate comprises a targeted agent and a chemokine receptor targeting agent, or a portion thereof, wherein the conjugate binds to a chemokine receptor resulting in internalization of the targeted agent in cells bearing the receptor.—

—56. The method of claim 55, wherein the conjugate comprises the following components: (chemokine receptor targeting agent)$_n$, (L)$_q$ and (targeted agent)$_m$, wherein:

L is a linker for linking the chemokine receptor targeting agent to a targeted agent;

chemokine receptor targeting agent is any moiety that selectively binds to a chemokine receptor;

m and n, which are selected independently, are at least 1; and

q is 0 or more as long as the resulting conjugate binds to the targeted receptor, is internalized and delivers the targeted agent;

the resulting conjugate binds to a receptor that interacts with and internalizes a chemokine, whereby the targeted agent(s) is internalized in a cell bearing the receptor; and

when the conjugate contains a plurality of targeted agents the targeted agents are the same or different, and when the conjugate contains a plurality of chemokine receptor targeting agents the targeting agents are the same or different.—

—57. The method of claim 55, wherein the chemokine receptor targeting agent is a chemokine, an antibody that specifically binds to a chemokine receptor or a fragment of the chemokine or antibody, wherein the fragment binds to the receptor and internalizes the targeted agent.—

—58. The method of claim 55, wherein the chemokine receptor targeting agent specifically binds to chemokine receptors on activated leukocytes.—

—59. The method of claim 55, wherein the chemokine receptor targeting agent specifically binds to chemokine receptors on cells selected from mononuclear phagocytes (MNP), leukocytes, natural killer cells, dendritic cells, T lymphocytes and B lymphocytes.—

—60. The method of claim 59, wherein the leukocytes are selected basophils, neutrophils, eosinophils, and combinations of any two or more thereof.—

—61. The method of claim 55, wherein the targeted agent is a toxin, a nucleic acid or a therapeutic protein.

—62. The method of claim 55, wherein the chemokine receptor targeting agent and targeted agent are linked directly via a covalent or ionic linkage.—

—63. The method of claim 55, wherein the chemokine receptor targeting agent and targeting agent are joined via a linker.—

—64. The method of claim 63, wherein the linker is a peptide linkage, a polypeptide or is chemical linker.—

Please amend claims 29, 38 and 40 follows:

29. (Amended) A method for treating inflammatory responses associated with activation, proliferation and migration of immune effector cells, comprising administering a conjugate[of claim 1] to an animal mammal, whereby an inflammatory response associated with activation, proliferation migration or the immune effector cells is inhibited, wherein the conjugate comprises a targeted agent and a chemokine receptor targeting agent, or a portion thereof, wherein the conjugate binds to a chemokine receptor resulting in internalization of the targeted agent in cells bearing the receptor.

38. (Amended) A method of inhibiting proliferation, migration or activation of cells bearing chemokine receptors, comprising contacting the cells with an effective amount of a conjugate [of claim 1] that comprises a targeted agent and a chemokine receptor targeting agent, or a portion thereof, wherein